skip to content
Primary navigation


Drug - Erleada™ (apalutamide) [Janssen Products, LP]

December 2018

Therapeutic area - Antineoplastic - Antiandrogenic Agents

Initial approval criteria

  • Patient has NON-metastatic castration-resistant prostate cancer (nmCRPC) AND
  • Patient is at least 18 years old AND
  • Patient will receive a gonadotropin-releasing hormone (GnRH)-analog or has had a bilateral orchiectomy
  • Initial approval is for 6 months

Renewal criteria

  • Patient continues to meet the above criteria AND
  • Tumor response with stabilization of disease or decrease in size of tumor or tumor spread AND
  • Absence of unacceptable toxicity from the drug
  • Renewal approval is for 6 months

Quantity limits

  • 136 tablets per 34 days


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top